Core Insights - The article presents new data from a proof-of-concept study on the detection of circulating tumor cells (CTCs) in glioblastoma patients, highlighting the effectiveness of the Parsortix label-free methodology [1] Company Overview - ANGLE plc is a leading company in the liquid biopsy sector, specializing in innovative CTC solutions for research, drug development, and clinical oncology [1] Study Details - The study involved 15 newly diagnosed, treatment-naïve glioblastoma (GBM) patients, with blood samples processed using the Parsortix® system and CellKeep™ slides [1]